Irinotecan Kabi

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Kabi, is a topoisomerase I inhibitor presented as a sterile intravenous solution for infusion use. It is employed in the treatment of metastatic colorectal cancer in adult patients.

GNH USA supplies Irinotecan Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Irinotecan Kabi is a topoisomerase I inhibitor used in the management of colorectal cancer. - Metastatic colorectal cancer: improves overall survival when combined with fluoropyrimidine‑based chemotherapy.

Irinotecan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Vomiting: occasional episodes during or after infusion. - Diarrhea: can be severe and require supportive care. - Neutropenia: reduced white blood cell count increasing infection risk. - Fatigue: generalized tiredness. - Alopecia: temporary hair loss.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count, a medical emergency. - Severe colitis: intense inflammation of the colon. - Hepatotoxicity: elevated liver enzymes or liver injury. - Anaphylactic reactions: rare but potentially life‑threatening hypersensitivity. - Tumor lysis syndrome: rapid tumor breakdown causing metabolic disturbances.

Before initiating therapy, clinicians should assess baseline health status and monitor patients closely. - Blood count monitoring: perform complete blood counts before each cycle. - Liver function assessment: evaluate hepatic enzymes and bilirubin levels. - Bowel obstruction risk: screen for prior gastrointestinal surgery or obstruction. - Antiemetic prophylaxis: administer anti‑nausea medication prior to infusion. - Dose adjustment: consider renal or hepatic impairment when dosing. - Store at controlled room temperature: keep in original container, protect from light and moisture.

Irinotecan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase SN‑38 exposure. - UGT1A1 inhibitors (e.g., atazanavir): raise risk of severe neutropenia. - Concurrent high‑dose irinotecan formulations: may cause cumulative toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): reduce drug exposure. - Anticoagulants (e.g., warfarin): may enhance bleeding risk. - Other myelosuppressive agents (e.g., carboplatin): increase bone‑marrow suppression.